Search

Your search keyword '"Craxì, A."' showing total 3,322 results

Search Constraints

Start Over You searched for: Author "Craxì, A." Remove constraint Author: "Craxì, A."
3,322 results on '"Craxì, A."'

Search Results

1. A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort

3. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

4. Inflammation and autonomic balance in cirrhosis: Association between sympathetic nervous system and osteopontin, interleukin‐22, interleukin‐6 and interleukin‐1Ra concentrations according to portal hypertension and disease severity

5. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

6. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

7. A global research priority agenda to advance public health responses to fatty liver disease

8. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

9. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

10. Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

12. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)

17. A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease

19. Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

20. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

21. What is the benefit of prophylaxis to prevent HBV reactivation in HBsAg‐negative anti‐HBc‐positive patients? Meta‐analysis and decision curve analysis.

22. Health Care at the Time of COVID-19

23. Liver transplantation for severe alcoholic hepatitis: A multicenter Italian study

24. Heart rate variability is associated with disease severity and portal hypertension in cirrhosis

27. First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials

28. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

29. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP)

31. Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes

32. Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study

33. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

34. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

36. Mer Tyrosine Kinase (MERTK) modulates liver fibrosis progression and hepatocellular carcinoma development

37. A systematic review on omics data (metagenomics, metatranscriptomics, and metabolomics) in the role of microbiome in gallbladder disease

39. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

42. The Equitable Benefit Approach to guide the assessment of medical and psychosocial factors in liver transplant candidacy.

44. Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic fatty liver disease

49. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

50. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Catalog

Books, media, physical & digital resources